By Carl C. Schuessler, Jr., DHP, DIA, GBDS
Organized crime – this is killing diabetics…………………
Humalog perfectly illustrates the gross-to-net bubble. Too many patients pay full price for essential drugs that are sold to insurers and PBMs at deep discounts.
Humalog prices have been off the chain over the past 5 yrs., the per-patient list price of Humalog rose by 52%, while the net price declined by 8%.
What’s more, the average annual value of Lilly’s per-patient rebates and discounts grew, from $2,928 in 2014 to $5,508 in 2018. Wake-up America!
